Newswire (Published: Monday, June 19, 2017, Received: Thursday, June 15, 2017, 10:37:46 PM CDT)

Word Count: 753

Tel Aviv University Reports Findings in Prostate Cancer (Does Choline PET/CT Change the Management of Prostate Cancer Patients With Biochemical Failure?)

By a News Reporter-Staff News Editor at Clinical Trials Week -- Data detailed on Oncology - Prostate Cancer have been presented. According to news reporting originating from Tel Aviv, Israel, by NewsRx correspondents, research stated, "The FDA approved C-11 choline PET/computed tomography (CT) for imaging patients with recurrent prostate cancer in 2012. Subsequently, the 2014 NCCN guidelines have introduced labeled choline PET/CT in the imaging algorithm of patients with suspected recurrent disease."

Our news editors obtained a quote from the research from Tel Aviv University, "However, there is only scarce data on the impact of labeled choline PET/CT findings on disease management. We hypothesized that labeled-choline PET/CT studies showing local or regional recurrence or distant metastases will have a direct role in selection of appropriate patient management and improve radiation planning in patients with disease that can be controlled using this mode of therapy. This retrospective study was approved by the Tel Aviv Sourasky and Sheba Medical Center'sHelsinki ethical review committees. Patient characteristics including age, PSA, stage, prior treatments, and pre-PET choline treatment recommendations based on NCCN guidelines were recorded. Patients with biochemical failure and without evidence of recurrence on physical examination or standard imaging were offered the option of additional imaging with labeled choline PET/CT. Treatment recommendations post-PET/CT were compared with pre-PET/CT ones. Pathologic confirmation was obtained before prostate retreatment. A nonparametric (2) test was used to compare the initial and final treatment recommendations following choline PET/CT. Between June 2010 and January 2014, 34 labeled-choline PET/CT studies were performed on 33 patients with biochemical failure following radical prostatectomy (RP) (n=6), radiation therapy (RT) (n=6), brachytherapy (n=2), RP+salvage prostate fossa RT (n=14), and RP+salvage prostate fossa/lymph node RT (n=6). Median PSA level before imaging was 2 ng/mL (range, 0.16 to 79). Labeled choline PET/CT showed prostate, prostate fossa, or pelvic lymph node increased uptake in 17 studies, remote metastatic disease in 9 studies, and failed to identify the cause for biochemical failure in 7 scans.PET/CT altered treatment approach in 18 of 33 (55%) patients (P=0.05). Sixteen of 27 patients (59%) treated previously with radiation were retreated with RT and delayed or eliminated androgen deprivation therapy: 1 received salvage brachytherapy, 10 received salvage pelvic lymph node or prostate fossa irradiation, 2 brachytherapy failures received salvage prostate and lymph nodes IMRT, and 3 with solitary bone metastasis were treated with radiosurgery. Eleven of 16 patients retreated responded to salvage therapy with a significant PSA response (<0.2 ng/mL), 2 patients had partial biochemical responses, and 3 patients failed. The median duration of response was 500447 days. Two of 6 patients with no prior RT were referred for salvage prostatic fossa RT: 1 received dose escalation for disease identified in the prostate fossa and another had inclusion of hot pelvic lymph nodes in the treatment volume."

According to the news editors, the research concluded: "These early results suggest that labeled choline PET/CT imaging performed according to current NCCN guidelines may change management and improve care in prostate cancer patients with biochemical failure by identifying patients for referral for salvage radiation therapy, improving radiation planning, and delaying or avoiding use of androgen deprivation therapy."

For more information on this research see: Does Choline PET/CT Change the Management of Prostate Cancer Patients With Biochemical Failure? American Journal of Clinical Oncology-Cancer Clinical Trials, 2017;40(3):256-259. American Journal of Clinical Oncology-Cancer Clinical Trials can be contacted at: Lippincott Williams & Wilkins, Two Commerce Sq, 2001 Market St, Philadelphia, PA 19103, USA (see also Oncology - Prostate Cancer).

The news editors report that additional information may be obtained by contacting Z. Symon, Tel Aviv University, Sackler Sch Med, Chaim Sheba Med Center, Dept. of Urol, Tel Aviv, Israel. Additional authors for this research include E. Even-Sapir, S. Ben-Haim, A. Saad, B. Spieler, T. Davidson, R. Berger, I. Weiss, S. Appel, Y.R. Lawrence and J. Goldstein.

Keywords for this news article include: Tel Aviv, Israel, Asia, Quaternary Ammonium Compounds, Trimethyl Ammonium Compounds, Clinical Trials and Studies, Hemic and Immune Systems, Radical Prostatectomy, Drugs and Therapies, Post-Trial Research, Prostatic Neoplasms, Diet and Nutrition, Lymphoid Tissue, Prostate Cancer, Micronutrient, Ethanolamines, Brachytherapy, Biochemicals, Biochemistry, Radiotherapy, Lymph Nodes, Immunology, Chemicals, Oncology, Surgery, Choline, Therapy, Tel Aviv University.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC


Lippincott Williams & Wilkins
Wolters Kluwer N.V.
Wolters Kluwer N.V.
Wolters Kluwer N.V.


      Medical Devices
            Medical Diagnostic Equipment
                  Medical Imaging Equipment
      Medical Device Manufacturing
            Medical Devices
                  Medical Diagnostic Equipment
                        Medical Imaging Equipment


North America
Northern Europe
Western Asia
United States
Tel Aviv


Science and Technology
      Scientific Research
Health and Wellness
      Medical Conditions and Diseases
                  Prostate Cancer
            Men's Health Issues
                  Prostate Cancer
      Medical Specialties and Practices
      Treatments and Therapies
            Medicinal Drugs